UDC

616.36-018-092.9:615.357

DOI

10.37482/2687-1491-Z248

Authors

Olga A. Makarova* ORCID: https://orcid.org/0000-0002-4093-2502
*Irkutsk State Medical University (Irkutsk, Russia)

Abstract

Thiamazole, used in the treatment of hyperthyroidism, has a hepatotoxic effect, resulting in side effects of varying severity, which dictates the need to find ways of correcting the state of the liver. The purpose of this study was to identify morphofunctional liver damage caused by prolonged use of thiamazole and the possibility of its correction with dalargin. Materials and methods. The research involved 30 white mongrel rats, who were divided into the control and two experimental groups, each consisting of 10 animals (1st, 2nd and 3rd group, respectively). Animals from the experemental groups received oral thiamazole at a dose of 10 mg/kg daily for 8 weeks. Rats in the 3rd group were administered with dalargin intramuscularly at a dose of 0.1 mg/kg daily for 2 days after discontinuation of thiamazole. The rats were then euthanized with ether; the liver was extracted, its mass was determined and, after histological processing, sections were prepared. To assess the condition of the liver, histological, histochemical, and morphometric methods were applied, and the volume fractions and mass of structural elements were evaluated, which allowed us to, either directly or indirectly, assess changes in not only the structure but also the function of the liver. Results. After prolonged administration of thiamazole, an inflammatory reaction was observed in the liver: the mass of the liver, connective tissue stroma and immature collagen in it increased, necrotization of the parenchyma intensified, sinusoids expanded and the intralobular blood flow was disrupted, glycogen and protein utilization stopped, and liver macrophages were activated. Injections of dalargin produced an anti-inflammatory effect: necrotization of the parenchyma and phagocytic activity of Kupffer cells decreased, intracellular blood flow normalized and the volume of the parenchyma was restored, glycogen and protein utilization was activated, and the mass of connective tissue stroma and immature collagen in it decreased. Thus, dalargin can effectively limit the inflammatory reaction in the liver.

Keywords

toxic liver damage, liver inflammation, anti-inflammatory effect of dalargin, hepatotoxicity of thiamazole, hepatotropicity of dalargin, hepatoprotectors

References

1. Molokanova Yu.P., Saprykin V.P. Issledovanie zabolevaemosti naseleniya tsentral’nogo regiona Rossiyskoy Federatsii boleznyami shchitovidnoy zhelezy [A Study on the Incidence of Thyroid Diseases in the Population of the Central Region of the Russian Federation]. Petrenko D.B. (ed.). Aktual’nye problemy biologicheskoy i khimicheskoy ekologii [Current Issues of Biological and Chemical Ecology]. Moscow, 2019, pp. 207–212.
2. Kuznetsov E.V., Zhukova L.A., Pakhomova E.A., Gulamov A.A. Endokrinnye zabolevaniya kak mediko-sotsial’naya problema sovremennosti [Endocrine Diseases as a Medical-Social Problem of Today]. Sovremennye problemy nauki i obrazovaniya, 2017, no. 4. Art. no. 62.
3. Savina A.A. Trends in the Incidence of Diseases of the Endocrine System of the Adult Population of the Russian Federation. Soc. Aspects Popul. Health, 2021, vol. 67, no. 4. Art. no. 6 (in Russ.).
4. Ross D.S., Burch H.B., Cooper D.S., Greenlee M.C., Laurberg P., Maia A.L., Rivkees S.A., Samuels M., Sosa J.A., Stan M.N., Walter M.A. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 2016, vol. 26, no. 10, pp. 1343–1421. https://doi.org/10.1089/thy.2016.0229
5. Bueverov A.O., Bogomolov P.O., Nechayeva O.A., Zilov A.V. Cause-and-Effect Relationship Between Thyroid and Liver Diseases. Med. Counc., 2021, vol. 15, pp. 88–94 (in Russ.). https://doi.org/10.21518/2079-701X-2021-15-88-94
6. Lazebnik L.B., Golovanova E.V., Hlynova O.V., Alekseenko S.A., Aryamkina O.L., Bakulin I.G., Bakulina N.V., Baranovsky A.Yu., Bondarenko O.A., Varganova A.N., Volkova T.V., Vologzhanina L.G., Volchegorsky I.A., Demicheva T.P., Dolgushina A.I., Mayev I.V., Minushkin O.N., Raykhelson K.L., Smirnova E.N., Tarasova L.V., Tsyganova Yu.V. Medicinal Liver Damage in Adults. Exp. Clin. Gastroenterol., 2020, vol. 174, no. 2, pp. 29–54 (in Russ.). https://doi.org/10.31146/1682-8658-ecg-174-2-29-54
7. Piantanida E., Ippolito S., Gallo D., Masiello E., Premoli P., Cusini C., Rosetti S., Sabatino J., Segato S., Trimarchi F., Bartalena L., Tanda M.L. The Interplay Between Thyroid and Liver: Implications for Clinical Practice. J. Endocrinol. Invest., 2020, vol. 43, no. 7, pp. 885–899. https://doi.org/10.1007/s40618-020-01208-6
8. Dedov I.I., Mel’nichenko G.A. (eds.). Endokrinologiya [Endocrinology]. Moscow, 2021. 1112 p.
9. Smakhtin M.Yu., Chulanova A.A., Smakhtina A.M. Effekty nekotorykh regulyatornykh peptidov na gepatoprotektornuyu i immunnuyu funktsii organizma [Effects of Some Regulatory Peptides on the Body’s Hepatoprotective and Immune Functions]. Universitetskaya nauka: vzglyad v budushchee [University Science: A Look into the Future]. Kursk, 2018, pp. 96–99.
10. Solin A.V., Lyashev Y.D., Tsygan N.V. Hepatoprotective Effect of Opioid Peptides in Stress. Res. Results Pharmacol., 2019, vol. 5, no. 1, pp. 77–96. https://doi.org/10.3897/rrpharmacology.5.34472
11. Fricker L.D., Margolis E.B., Gomes I., Devi L.A. Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions. Mol. Pharmacol., 2020, vol. 98, no. 2, pp. 96–108. https://doi.org/10.1124/mol.120.119388
12. Liashev A.Y., Mal G.S., Solin A.V., Balanina M. The Effect of Dalargin on Growth Factors Content in Experimental Ulcerative Colitis. Res. Results Pharmacol., 2024, vol. 10, no. 1, pp. 67–73. https://doi.org/10.18413/rrpharmacology.10.430
13. Lyashev Yu.D., Tsygan N.V., Solin A.V. Korrektsiya opioidnymi peptidami stress-indutsirovannykh porazheniy pecheni [Correction of Stress-Induced Liver Damage with Opioid Peptides]. Kursk, 2021. 204 p.
14. Chartakov K., Razakov B.Yu. Eksperimental’nye modeli patologii shchitovidnoy zhelezy [Experimental Models of Thyroid Pathology]. Mirovaya nauka, 2024, no. 4, pp. 80–83.
15. Merkulov G.A. Kurs patologogistologicheskoy tekhniki [A Course of Pathohistological Technology]. Leningrad, 1969. 423 p.
16. Medzhitov R. The Spectrum of Inflammatory Responses. Science, 2021, vol. 374, no. 6571, pp. 1070–1075. https://doi.org/10.1126/science.abi5200
17. Yorke E. Co-Morbid Hypothyroidism and Liver Dysfunction: A Review. Clin. Med. Insights Endocrinol. Diabetes, 2024, vol. 17. https://doi.org/10.1177/11795514241231533
18. Rasulova M.T., Nishantaev M.K., Yuldashev N.M. Funktsional’no-metabolicheskoe sostoyanie monooksigenaznoy sistemy pecheni pri eksperimental’nom gipo- i gipertireoze [Functional Metabolic State of the Monooxygenase System of the Liver in Experimental Hypo- and Hyperthyroidism]. Novyy den’ v meditsine, 2019, no. 4, pp. 414–418.
19. Ibragimov V.R., Kozlov V.N., Kas’yanova Yu.V., Timerbulatova G.R. Vliyanie tireostaticheskikh preparatov na gistostrukturu pecheni krys v eksperimente [The Influence of the Thyreostatic Medications on the Histostructure of Liver]. Pracì TDATU, 2012, vol. 12, no. 2, pp. 141–146.
20. Milaev A.V., Lindover V.S., Galukhina E.A., Mochalova A.D., Dedanishvili N.S. Vliyanie gipertireoza na transaktivatsiyu perisinusoidal’nykh kletok pecheni krys v modeli zhirovogo gepatoza [Effect of Hyperthyroidism on the Transactivation of Hepatic Stellate Cells in Rats in a Fatty Liver Disease Model]. FORCIPE, 2022, vol. 5, no. S3, p. 893.